A triple-receptor agonist studied for its simultaneous activation of GLP-1, GIP, and glucagon pathways — the most complex receptor profile in metabolic peptide research. Phase 3 TRIUMPH-4 results: 28.7% body weight loss at 12mg dose.
Retatrutide (LY3437943) is a synthetic peptide developed by Eli Lilly that simultaneously activates three distinct receptor systems: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. While GLP-1 agonists like semaglutide target a single receptor, and dual agonists like tirzepatide work on two receptors, Retatrutide represents a third generation of multi-receptor metabolic pharmacology. The addition of glucagon receptor agonism — which directly drives energy expenditure and hepatic fat oxidation — is what separates its mechanism from all predecessors.
As of late 2025, Retatrutide has completed its first Phase 3 trial (TRIUMPH-4) and has eight Phase 3 trials currently active across three programs: TRIUMPH (obesity), TRANSCEND (type 2 diabetes), and SYNERGY (MASLD/liver disease). The complete trial program has enrolled over 5,800 participants. TRIUMPH-4 top-line data released in December 2025 showed 28.7% average body weight reduction at the 12mg dose — the highest ever recorded in a Phase 3 obesity trial, rivaling bariatric surgery outcomes. Remaining trial readouts are expected throughout 2026, with a potential NDA filing in late 2026 and FDA approval around mid-to-late 2027.
📡 Weekly peptide research updates — regulatory updates, new compound profiles, COA alerts.
⚠️ FDA PCAC: -- days leftNo spam. Unsubscribe anytime. 7 peptides under review — see what's at stake →
Retatrutide's triple receptor profile makes it a uniquely valuable tool for investigating how metabolic pathways interact when activated in combination. The TRIUMPH-4 Phase 3 data delivered the most striking efficacy numbers ever recorded in a Phase 3 obesity trial.
7 free research tools built around exactly this kind of compound data. No paywall, no credit card.
Retatrutide binds to and activates GLP-1 receptors (stimulating insulin release and slowing gastric emptying), GIP receptors (enhancing insulin response and potentially supporting fat tissue regulation), and glucagon receptors (increasing energy expenditure). The three-pathway activation creates a layered metabolic effect that each individual target cannot produce alone. Researchers are still working to disentangle how much of the observed effect comes from each receptor arm, and how the three systems interact when activated simultaneously by a single molecule.
Think of your metabolic system like a concert with three conductors who normally work in separate venues. GLP-1 conducts the insulin orchestra. GIP fine-tunes the backup singers. Glucagon runs the energy department's lighting crew. Retatrutide is like putting all three conductors on the same stage at the same time — the combined performance is different from what any one of them could produce solo.
Research Disclaimer: The following reflects published clinical and preclinical research and is not medical advice. Consult a licensed healthcare provider before making any health decisions.
Retatrutide (LY3437943) has completed Phase 1 and Phase 2 trials, with the first Phase 3 readout (TRIUMPH-4) published in December 2025. Phase 2 data — published by Jastreboff et al. (2023, New England Journal of Medicine) — established the dose-response relationship across 1, 2, 4, 8, and 12 mg weekly doses in 338 participants over 48 weeks. This makes retatrutide one of the few triple-agonist compounds with peer-reviewed Phase 2 dose-ranging data available.
Key References: Jastreboff AM et al. (2023). "Triple-hormone-receptor agonist retatrutide for obesity — a Phase 2 trial." New England Journal of Medicine, 389(6), 514–526. · Eli Lilly press release (December 2025). TRIUMPH-4 Phase 3 top-line results (NCT05931367). · Bergmann NC et al. (2023). Retatrutide Phase 1 safety and PK. Diabetes, Obesity and Metabolism.
TRIUMPH-4 was a 68-week, randomized, double-blind, placebo-controlled trial in 445 participants with obesity or overweight and moderate-to-severe knee osteoarthritis (84% with baseline BMI ≥35). It is the first completed Phase 3 trial in the TRIUMPH program and delivered the highest weight loss outcomes ever recorded in a Phase 3 trial of any anti-obesity compound.
| Outcome | 9mg Dose | 12mg Dose | Placebo |
|---|---|---|---|
| Avg. body weight reduction | 26.4% (64.2 lbs) | 28.7% (71.2 lbs) | 2.1% (4.6 lbs) |
| ≥25% weight loss achieved | — | 58.6% of participants | — |
| ≥30% weight loss achieved | — | 39.4% of participants | — |
| WOMAC knee pain reduction | — | 75.8% improvement | — |
| Systolic blood pressure | — | −14.0 mmHg | — |
Source: Eli Lilly press release, December 2025. TRIUMPH-4 (NCT05931367). Full data pending peer-reviewed publication.
TRIUMPH-4 is the first readout. Seven additional trials are active, with results expected throughout 2026:
Researchers sourcing Retatrutide for laboratory work should understand the current legal and regulatory landscape — it directly affects compound availability and pricing.
The 28.7% average body weight loss in TRIUMPH-4 is the highest ever recorded in a Phase 3 clinical trial for any anti-obesity compound — exceeding all prior GLP-1 and GLP-1/GIP agonists and approaching the range of bariatric surgery (typically 25–35% excess weight loss).
TRIUMPH-4's knee osteoarthritis data was a surprise. 12% of participants on the 12mg dose were completely pain-free at 68 weeks vs. 4.2% on placebo — an unexpected finding that has opened new research questions about how metabolic improvement affects joint inflammation.
Creating a single molecule that activates three receptor classes at appropriate ratios is considered one of the hardest problems in peptide medicinal chemistry. Glucagon without adequate GLP-1 co-agonism would raise blood sugar — the balance engineering took Eli Lilly years to perfect.
Every batch of Retatrutide with full Certificate of Analysis documentation.